J Korean Neuropsychiatr Assoc.  2019 Feb;58(1):55-63. 10.4306/jknpa.2019.58.1.55.

Reliability and Validity of the Korean Version of the Birchwood Insight Scale

Affiliations
  • 1Department of Psychiatry, Dongguk University Ilsan Hospital, Goyang, Korea.
  • 2Institute of Clinical Psychopharmacology, Dongguk University College of Medicine, Goyang, Korea.
  • 3Department of Medicine, Dongguk University Graduate School, Gyeongju, Korea. psw0124@hanmail.net

Abstract


OBJECTIVES
In the treatment of schizophrenia, treatment compliance is an important prognostic factor. As insight has a significant impact on treatment compliance, an appropriate assessment of insight is essential in the treatment of schizophrenia. This study examined the reliability and validity of the Korean version of Birchwood Insight Scale (BIS).
METHODS
Fifty seven adult patients diagnosed with schizophrenia according to DSM-5 were recruited from a university hospital. They were evaluated using the Positive and Negative Syndrome Scale (PANSS), The Scale to Assessment Unawareness of Mental Disorder (SUMD) and BIS. Explorative factor analysis was performed to examine the construct validity of the Korean version of BIS. Concurrent validity was evaluated by a comparison with the PANSS G12 item and SUMD. The test-retest correlation was evaluated to examine the test-retest reliability. Multiple regression analysis was performed to examine the variables affecting insight.
RESULTS
Explorative factor analysis showed that the Korean version of BIS was composed of 2 factors, which are "˜Awareness of symptoms' and "˜Awareness of illness and need for treatment.' The Korean version of BIS was reliable in terms of the internal consistency. Concurrent validity with the PANSS G 12 item and SUMD was statistically significant. The test-retest reliability was also statistically significant. Multiple regression analysis showed that the PANSS negative factor affects the BIS score, indicating that negative symptoms of schizophrenia may impair insight of the illness.
CONCLUSION
This study suggests that the Korean version of BIS is a valid and reliable tool for assessing the insight of patients with schizophrenia.

Keyword

Schizophrenia; Insight; Psychopathology; Negative symptom; Self-Rating Scale

MeSH Terms

Adult
Compliance
Humans
Mental Disorders
Psychopathology
Reproducibility of Results*
Schizophrenia

Reference

1. Cleary SD, Bhatty S, Broussard B, Cristofaro SL, Wan CR, Compton MT. Measuring insight through patient self-report: an in-depth analysis of the factor structure of the Birchwood Insight Scale. Psychiatry Res. 2014; 216:263–268.
Article
2. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry. 1993; 150:873–879.
Article
3. Monteiro LC, Silva VA, Louzã MR. Insight, cognitive dysfunction and symptomatology in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2008; 258:402–405.
Article
4. Brent BK, Giuliano AJ, Zimmet SV, Keshavan MS, Seidman LJ. Insight into illness in patients and caregivers during early psychosis: a pilot study. Schizophr Res. 2011; 127:100–106.
Article
5. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O'callaghan E. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry. 1998; 39:215–219.
Article
6. Rüsch N, Corrigan PW. Motivational interviewing to improve insight and treatment adherence in schizophrenia. Psychiatr Rehabil J. 2002; 26:23–32.
Article
7. Lysaker PH, Dimaggio G, Buck KD, Callaway SS, Salvatore G, Carcione A, et al. Poor insight in schizophrenia: links between different forms of metacognition with awareness of symptoms, treatment need, and consequences of illness. Compr Psychiatry. 2011; 52:253–260.
Article
8. Hillis JD, Leonhardt BL, Vohs JL, Buck KD, Salvatore G, Popolo R, et al. Metacognitive reflective and insight therapy for people in early phase of a schizophrenia spectrum disorder. J Clin Psychol. 2015; 71:125–135.
Article
9. Aleman A, Agrawal N, Morgan KD, David AS. Insight in psychosis and neuropsychological function. Br J Psychiatry. 2006; 189:204–212.
10. Burton CZ, Twamley EW. Neurocognitive insight, treatment utilization, and cognitive training outcomes in schizophrenia. Schizophr Res. 2015; 161:399–402.
Article
11. Fervaha G, Foussias G, Agid O, Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr Scand. 2014; 130:290–299.
Article
12. Shad MU, Muddasani S, Prasad K, Sweeney JA, Keshavan MS. Insight and prefrontal cortex in first-episode schizophrenia. Neuroimage. 2004; 22:1315–1320.
Article
13. Sapara A, Cooke M, Fannon D, Francis A, Buchanan RW, Anilkumar AP, et al. Prefrontal cortex and insight in schizophrenia: a volumetric MRI study. Schizophr Res. 2007; 89:22–34.
Article
14. Ha TH, Youn T, Ha KS, Rho KS, Lee JM, Kim IY, et al. Gray matter abnormalities in paranoid schizophrenia and their clinical correlations. Psychiatry Res. 2004; 132:251–260.
Article
15. Sapara A, Ffytche DH, Cooke MA, Williams SC, Kumari V. Voxelbased magnetic resonance imaging investigation of poor and preserved clinical insight in people with schizophrenia. World J Psychiatry. 2016; 6:311–321.
Article
16. Drake RJ, Lewis SW. Insight and neurocognition in schizophrenia. Schizophr Res. 2003; 62:165–173.
Article
17. Morgan KD, Dazzan P, Morgan C, Lappin J, Hutchinson G, Suckling J, et al. Insight, grey matter and cognitive function in first-onset psychosis. Br J Psychiatry. 2010; 197:141–148.
Article
18. Liemburg EJ, Van der Meer L, Swart M, Curcic-Blake B, Bruggeman R, Knegtering H, et al. Reduced connectivity in the self-processing network of schizophrenia patients with poor insight. PLoS One. 2012; 7:e42707.
Article
19. Spalletta G, Piras F, Piras F, Caltagirone C, Orfei MD. The structural neuroanatomy of metacognitive insight in schizophrenia and it psychopathological and neuropsychological correlates. Hum Brain Mapp. 2014; 35:4729–4740.
Article
20. Nair A, Palmer EC, Aleman A, David AS. Relationship between cognition, clinical and cognitive insight in psychotic disorders: a review and meta-analysis. Schizophr Res. 2014; 152:191–200.
Article
21. Shad MU, Keshavan MS. Neurobiology of insight deficits in schizophrenia: an fMRI study. Schizophr Res. 2015; 165:220–226.
Article
22. Lin IF, Spiga R, Fortsch W. Insight and adherence to medication in chronic schizophrenics. J Clin Psychiatry. 1979; 40:430–432.
23. Amador XF, Strauss DH, Yale SA, Gorman JM. Awareness of illness in schizophrenia. Schizophr Bull. 1991; 17:113–132.
Article
24. David AS. Insight and psychosis. Br J Psychiatry. 1990; 156:798–808.
Article
25. Saravanan B, Jacob KS, Prince M, Bhugra D, David AS. Culture and insight revisited. Br J Psychiatry. 2004; 184:107–109.
Article
26. Jacob KS. Insight in psychosis: standards, science, ethics and value judgment. Int J Soc Psychiatry. 2017; 63:345–351.
Article
27. McCabe R, Priebe S. The therapeutic relationship in the treatment of severe mental illness: a review of methods and findings. Int J Soc Psychiatry. 2004; 50:115–128.
Article
28. Saravanan B, Jacob KS, Johnson S, Prince M, Bhugra D, David AS. Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathology. Br J Psychiatry. 2010; 196:454–459.
Article
29. McEVOY JP, Apperson LJ, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, et al. Insight in schizophrenia. Its relationship to acute psychopathology. J Nerv Ment Dis. 1989; 177:43–47.
Article
30. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report insight scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand. 1994; 89:62–67.
Article
31. Marks KA, Fastenau PS, Lysaker PH, Bond GR. Self-Appraisal of Illness Questionnaire (SAIQ): relationship to researcher-rated insight and neuropsychological function in schizophrenia. Schizophr Res. 2000; 45:203–211.
Article
32. Marková IS, Berrios GE. The assessment of insight in clinical psychiatry: a new scale. Acta Psychiatr Scand. 1992; 86:159–164.
Article
33. Jovanovski D, Zakzanis KK, Atia M, Campbell Z, Young DA. A comparison between a researcher-rated and a self-report method of insight assessment in chronic schizophrenia revisited: a replication study using the SUMD and SAIQ. J Nerv Ment Dis. 2007; 195:165–169.
Article
34. Karow A, Pajonk FG, Reimer J, Hirdes F, Osterwald C, Naber D, et al. The dilemma of insight into illness in schizophrenia: self-and expertrated insight and quality of life. Eur Arch Psychiatry Clin Neurosci. 2008; 258:152–159.
Article
35. Jeong SH, Chung IW, Jung HY, Hwang SS, Kim SH, Youn T, et al. Comparison of clinician-rated and self-report insight in Korean patients with schizophrenia using VAGUS insight scale. Psychiatry Res. 2017; 258:93–100.
Article
36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). 5th ed. Washington DC: American Psychiatric Association;2013.
37. Roncone R, Tozzini C, Mazza M, De Risio A, Giosuè P, Morosini P, et al. [Validation of the Italian version of the self-report insight scale]. Epidemiol Psichiatr Soc. 2003; 12:63–75.
Article
38. Song JY, Kim KT, Lee SK, Kim YH, Noh JH, Kim JW, et al. Reliability and validity of the Korean version of the scale to assessment unawareness of mental disorder (SUMD-K). J Korean Neuropsychiatr Assoc. 2006; 45:307–315.
39. Michel P, Baumstarck K, Auquier P, Amador X, Dumas R, Fernandez J, et al. Psychometric properties of the abbreviated version of the scale to assess unawareness in mental disorder in schizophrenia. BMC Psychiatry. 2013; 13:229.
Article
40. Kay SR, Fiszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13:261–276.
Article
41. Yi JS, Ahn YM, Shin HK, An SK, Joo YH, Kim SH, et al. Reliability and validity of the Korean version of the positive and negative syndrome scale. J Korean Neuropsychiatr Assoc. 2001; 40:1090–1105.
42. Hwang SS, Chang JS, Lee KY, Ahn YM, Kim YS. The causal model of insight in schizophrenia based on the positive and negative syndrome scale factors and the structural equation modeling. J Nerv Ment Dis. 2009; 197:79–84.
Article
43. Gilleen J, Greenwood K, David AS. Domains of awareness in schizophrenia. Schizophr Bull. 2010; 37:61–72.
Article
44. Gerretsen P, Remington G, Borlido C, Quilty L, Hassan S, Polsinelli G, et al. The VAGUS insight into psychosis scale–self-report and clinician-rated versions. Psychiatry Res. 2014; 220:1084–1089.
Article
45. Huang M, Huang Y, Yu L, Hu J, Chen J, Jin P, et al. Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia. BMC Psychiatry. 2016; 16:344.
Article
46. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004; 68:1–9.
Article
47. MacBeth A, Gumley A, Schwannauer M, Carcione A, Fisher R, McLeod HJ, et al. Metacognition, symptoms and premorbid functioning in a first episode psychosis sample. Compr Psychiatry. 2014; 55:268–273.
Article
48. Hutcheson GD, Sofroniou N. The multivariate social scientist: introductory statistics using generalized linear models. LA: Sage Publications;1999.
Full Text Links
  • JKNA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr